About: http://data.cimple.eu/news-article/1d106b1028d46fcd65973ca4c78f80e78138639d41cbca7e4dc6a317

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/1d106b1028d46fcd65973ca4c78f80e78138639d41cbca7e4dc6a317 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pfizer reaffirmed its 2020 profit forecast Tuesday following solid results that showed a mixed effect of the COVID-19 crisis on medical product sales. Revenues at the pharmaceutical giant were dented by the halt to non-essential surgeries, and Pfizer also ceased in-person meetings with healthcare professionals in many markets, impeding prescriptions of some new drugs. But Pfizer also pointed to increased sales of drugs stemming from consumers seeking to avoid pharmaceutical visits. Some products also got a boost from their apparent use to treat COVID-19, even though they have not been approved for that use, the company said. Net income came in at $3.4 billion, 12 percent below last year, which translated into per-share results that topped analyst expectations. Revenues declined eight percent to $12.0 billion. Pfizer confirmed its full-year forecasts for revenues and adjusted profits, while tweaking a number of other aspects of its outlook. It also said it faces no liquidity problems for "the forseeable future." Pfizer boosted by $500 million the range of its research and development budget for spending on a potential vaccine for COVID-19 as well as evaluation of existing products to treat the virus. Pfizer saw an increase in some medicines that it believes have been used in response to COVID-19, including Prevnar 13, a vaccine for pneumococcal pneumonia as well as some sterile injectable products used for patients on ventilators. "None of these products are approved for the treatment of COVID-19 and, therefore, Pfizer does not know the benefit/risk profile for their use in this disease," the company said. Pfizer halted recruitments for some new clinical trials in March, but resumed the activities in late April. The company has not had problems distributing its products, in part thanks to "newly available commercial air capacity to transport inventory," it said. Shares rose 2.0 percent in pre-market trading to $39.10. jmb/jm
schema:headline	Pfizer confirms forecast, sees mixed COVID-19 impact on sales
schema:mentions	Dented Records Bacterial pneumonia Medication Virus Pfizer Vaccine Severe acute respiratory syndrome coronavirus 2 Pneumococcal conjugate vaccine Net income Market liquidity Microsoft Outlook
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-04-28 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	74 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software